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Abstract
Background: Bioresorbable vascular scaffold (BVS) implantation is a new, promising treat-
ment method of coronary artery disease. Preliminary data in patients with stable angina are 
encouraging. However, the utility of BVS was not sufficiently evaluated in the setting of acute 
thrombotic lesions. The aim of this study was an optical coherence tomography (OCT) assess-
ment of acute procedural result of the everolimus-eluting BVS implantation in patients with 
ST segment elevation myocardial infarction (STEMI) and evaluation of mid-term clinical 
outcomes.
Methods: OCT examination was conducted in 23 STEMI patients who underwent primary 
angioplasty with BVS implantation. Off-line qualitative and quantitative coronary angiogra-
phy and OCT analyses were performed by an independent core laboratory.
Results: Successful procedural and clinical results were achieved in 95.7% of patients, and 
device success was observed in all patients. In OCT evaluation, most of the struts (95.4 ±  
± 7.96%) were well apposed, 4.6 ± 5.71% were classified as malapposed. The final minimum 
lumen diameter was 2.6 ± 0.35 mm, minimum scaffold area was 6.9 ± 1.54 mm2 and final 
residual stenosis was 8.8 ± 24.37%. Edge dissections were found in 3 (7.7%) lesions. Median 
follow-up period was 229 (interquartile range 199–248) days. One myocardial infarction, due 
to sub-acute stent thrombosis, occurred in a patient who discontinued pharmacotherapy.
Conclusions: The study shows that everolimus-eluting BVS implantation in STEMI is safe 
and feasible. The OCT evaluation confirmed excellent acute performance with appropriate 
scaffold expansion and low rate of malapposition. (Cardiol J 2015; 22, 3: 315–322)
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Introduction
Everolimus-eluting bioresorbable vascular 
scaffold (BVS) is an interesting new technology 
recently applied in the treatment of coronary ar-
tery lesions that might overcome the limitations 
of the currently used drug eluting stents (DES). 
Favorable features of BVS involve restoration of 
native vessel vasomotion, prevention of expansive 
remodeling, improvement of plaque stability, late 
lumen enlargement and potential avoidance of 
long-term complications, such as stent thrombosis, 
restenosis and neoatherosclerosis [1–4]. These 
beneficial effects were confirmed in preliminary 
studies in patients with stable coronary artery 
disease [4–12]. However, the utility of BVS was 
not sufficiently evaluated in the setting of acute 
coronary syndromes characterized by a different 
plaque pathomorphology. Acute thrombothic le-
sions with a large thrombus burden predispose to 
distal embolization and no-reflow syndrome, as 
well as to increased risk of stent malapposition. 
The latter phenomenon is associated with the 
dissolution of the thrombus sequestrated between 
the BVS struts and the vessel wall [13, 14]. There 
are only few reports with a comprehensive opti-
cal coherence tomography (OCT) evaluation of 
the BVS implantation in this group of patients 
[15, 16]. To add more data to the current limited 
body of evidence, we performed a pilot study with 
a qualitative and quantitative OCT examination 
to assess vessels’ response to the implanted BVS 
and the performance of the new device in culprit 
lesions in patients presenting with ST segment 
elevation myocardial infarction (STEMI).
Methods
In this single-center, prospective registry, 
23 patients with STEMI, who underwent primary 
percutaneous coronary intervention (pPCI) with 
implantation of at least one BVS, ABSORB™ 
(Abbott Vascular, Santa Clara, CA, USA) between 
March and August 2013 at the 1st Department 
of Cardiology at Warsaw Medical University, 
were included. Enrolled patients were older than 
18 years, had chest pain below 12 h and met elec-
trocardiographic criteria of STEMI according to 
the European Society of Cardiology guidelines 
[17]. Angiographic inclusion criteria involved de 
novo native coronary artery lesions in vessels with 
diameter between 2.5 and 3.8 mm (compatible with 
the use of a 2.5, 3.0 or 3.5 mm BVS). Major clinical 
exclusion criteria were: cardiogenic shock, pre-
hospital cardiac arrest, severe heart failure with 
left ventricular ejection fraction (LVEF) < 30%, 
contraindications for antiplatelet therapy, known 
contrast intolerance, pregnancy, malignant disease 
and participation in other investigational drug and 
device studies. Angiographic exclusion criteria 
were: left main coronary artery lesions, multives-
sel disease qualified for surgery, lesions involving 
a large side branch (diameter > 2.5 mm), massive 
calcifications, and arteries < 2.5 mm in diameter.
The protocol was approved by the local Ethics 
Committee and all patients gave written informed 
consent before inclusion.
Dual antiplatelet therapy was planned to be 
continued for 12 months after pPCI according to the 
current guidelines on the management of patients 
presenting with STEMI [17]. The administration 
of glycoprotein IIb/IIIa inhibitors was left to the 
operator’s discretion.
Detailed characteristics of BVS implanted in 
this study have been previously described [18–20]. 
Briefly, the scaffold is made of a polymer back-
bone of poly-L-lactide (PLLA) covered with a thin 
layer of a 1:1 mixture of poly-D,L-lactide polymer 
(PDLLA). Both materials are completely bioresorb-
able within approximately 2 to 3 years. The ester 
bonds of these polymers are hydrolyzed into lactate 
and its oligomers are further metabolized in the 
Krebs cycles. Antiproliferative drug everolimus 
is integrated in this balloon-expandable device in 
the concentration of 100 mg/cm2 of the scaffold and 
80% of the whole everolimus load is eluted within 
the first 30 days.
Coronary angiography and OCT analyses
Coronary angiography and pPCI were per-
formed by experienced interventional cardiologists. 
Post procedure OCT examination was conducted 
with a commercially available C7 OCT imaging 
system with Dragonfly® image wires (LightLab Im-
aging Inc., Westford, Massachusetts, US). Off-line 
qualitative and quantitative coronary angiography 
(QCA) and OCT analyses were performed by an 
independent core laboratory (Krakow Cardiovas-
cular Research Institute, Krakow, Poland). The 
QCA analysis was performed using Cardiovascular 
Angiography Analysis System 5.7.1 (Pie Medical 
Imaging Systems, Maastricht, the Netherlands) 
with the methodology already reported [21], and 
included: lesion length, minimum luminal diam-
eter (MLD), reference vessel diameter (RVD), 
maximal diameter at segment (Dmax), percentage of 
diameter stenosis (%DS), angiographic measures 
of perfusion (Thrombolysis In Myocardial Infarc-
tion [TIMI], and myocardial blush grade [MBG]). 
The thrombus grade was assessed based upon 
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the previously described 6-grade scale [22]). The 
Dmax represents the two single largest values of 
reference diameters observed in the segments 
proximal or distal to the lesion. The RVD is the 
virtual reference diameter measured at the site of 
the MLD prior to the scaffold implantation. Acute 
gain was calculated as post-procedural MLD minus 
pre-procedural MLD, and in case of pre-procedural 
total occlusion of culprit vessel, the MLD value was 
considered equal to zero.
The OCT measurements using the LightLab 
OCT imaging proprietary software were done by 
analysts blinded to the angiographic data. The quan-
titative and qualitative OCT assessment was based 
on previously described methodology [4, 23–25].
Scaffold analyses were performed in 1-mm 
longitudinal intervals. Quantitative measurements 
were performed at the abluminal surface of the 
struts and included lumen and scaffold areas and 
diameters. The OCT evaluation also involved the 
calculation of lumen areas and diameters at refer-
ence sites. Residual area stenosis was calculated 
as: (1 – [minimum scaffold area/maximum lumen 
area at reference site]) × 100. Strut and vessel wall 
interaction was defined in every single scaffold strut 
as complete apposition or malapposition (Figs. 1–3).
Success rates were defined as in previous 
studies with BVS implantation [15, 16]. Device 
success was described as the presence of residual 
diameter stenosis < 30% of the segment of the 
culprit lesion, covered by the BVS, assessed by an-
giographic visual estimation. Bailout stenting was 
not considered a device failure. Procedural success 
was defined as a device success with final TIMI 3 
flow and no major periprocedural complications, 
such as coronary perforation requiring pericardial 
drainage, emergent coronary artery bypass graft 
or flow-limiting dissection. Clinical success was 
defined as procedural success and no in-hospital 
major adverse cardiac events (MACE) including 
death, stroke/transient ischemic attack and new 
myocardial infarction (MI).
Patients were scheduled for a 30-day, 6- and 
12-month clinical evaluation. MACE incidence 
rates were recorded involving all-cause death, 
non-fatal MI, target lesion revascularization (TLR), 
target vessel revascularization (TVR), non-TVR 
and scaffold thrombosis. Additionally, angiographic 
and OCT evaluation were planned at the 12th and 
24th month after the index procedure. MI and scaffold 
thrombosis were defined according to the Academic 
Research Consortium definition [26]. Statistical 
Figure 1. Methodology of optical coherence tomography images analysis; A. Complete apposition of struts and 
absence of tissue prolapse; B. Scaffold malapposition; A’, B’. Optical coherence images with delineated shapes of 
scaffold area, lumen area and incomplete scaffold area (ISA Area).
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Figure 3. Optical coherence tomography image follow­
ing bioresorbable vascular scaffold implantation con­
firm complete apposition of the scaffold and reveal 
some thrombus protrusions through scaffold’s struts 
(arrow).
analysis was performed using the JMP software, 
version 9.0.0 (SAS Institute Cary, NC, USA). All 
values are expressed as mean ± standard deviation 
(continuous variables) or as count and percentage 
(categorical variables).
Results
The patient baseline characteristics are pre-
sented in Table 1. A total of 23 patients with STEMI 
were prospectively enrolled. Two patients received 
2 scaffolds in different, non-overlapping sites (sec-
ond culprit lesion). Another 3 patients required 
2 overlapping scaffolds due to edge dissection, 
eventually 28 BVS were implanted in 23 vessels 
including: left anterior descending artery (17.4%, 
n = 4), circumflex artery (17.4%, n = 4), obtuse 
marginal branch (4.4%, n = 1) and right coronary 
artery (60.8%, n = 14). Procedural and clinical 
success were achieved in 95.7% of the study 
population and device success was observed in the 
entire group. Manual aspiration thrombectomy was 
performed in 13 (56.5%) cases with totally occluded 
culprit artery (TIMI 0). Direct scaffold implantation 
Figure 2. Bioresorbable vascular scaffold implantation in a culprit right coronary artery (RCA); A. Coronary angio­
graphy demonstrating a culprit lesion in the proximal­RCA (arrow); B. Manual aspiration thrombectomy — a radio­
paque marker at distal end of aspiration catheter (arrow); C. Predilatation with a 2.0/15 mm semi­compliant balloon; 
D. Angiography following implantation of a 3.0/18 mm bioresorbable vascular scaffold.
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was done in 5 (21.7%) patients; 15 (65.2%) patients 
required postdilatation. Final %DS was 11.4 ± 
± 9.45%. TIMI 3 flow and MBG 3 were achieved in 
95.7% and 78.3% of patients, respectively. Baseline 
angiographic characteristics and procedural data 
are shown in Tables 2 and 3.
The OCT examination was performed in all 
patients after optimal angiographic result was 
achieved. In 5 (21.7%) cases, the operator decided 
to perform additional postdilatation because of scaf-
fold malapposition and/or device underexpansion 
revealed by OCT.
OCT data from 3 patients were excluded 
from further evaluation due to insufficient quality 
of obtained images. The final OCT data of 20 pa-
tients (25 scaffolds) are presented in Table 4. The 
scaffold length by OCT was 23.4 ± 8.42 mm that 
was comparable with QCA measurements (21.8 ± 
± 8.75 mm). Similarly, the results of in-scaffold 
MLD did not differ in both imaging modalities (2.5 ± 
± 0.40 mm and 2.6 ± 0.35 mm, for OCT and QCA, 
respectively). Minimum scaffold area in OCT was 
6.9 ± 1.54 mm2 and final residual area stenosis 
was 8.8 ± 24.37%. Edge dissections were found in 
3 (12.0%) lesions — in all cases in proximal refer-
ence. The scaffold expansion was symmetrical and 
no disruptions or discontinuities of scaffold struc-
ture, such as overhanging struts, were observed. 
Out of 4,019 analyzed struts, 95.4 ± 7.96% were 
completely apposed, malapposition was found in 
4.6 ± 5.71%. There were only 2 (8.0%) scaffolds 
in which more than 5% of malapposed struts were 
found. Qualitative OCT assessment immediately 
after implantation revealed a preserved box ap-
pearance in all struts.
OCT intra- and inter-observer variability 
analysis of lumen area and scaffold area performed 
in a single region of interest were good. For intra-
observer, mean difference was –0.04 ± 0.15 mm2 
(–0.56% ± 2.05%) for lumen area and –0.03 ± 
± 0.16 mm2 (0.32% ± 2.07%) for scaffold area. For 
inter-observer, mean difference was 0.24 ± 0.35 mm2 
(2.69% ± 3.79%) for lumen area and –0.28 ± 
± 0.24 mm2 (2.90% ± 2.54%) for scaffold area.
Complete follow-up was available in 21 (91.3%) 
patients with a median time of 229 days (inter-
quartile range 199–248 days) — the results are 
presented in Table 5. One patient who discontin-
ued pharmacotherapy had a non-fatal MI due to 
sub-acute stent thrombosis on the 9th day after 
BVS implantation (5 days after discontinuation of 
antiplatelet drugs). The TLR (and TVR) in this 
case involved manual aspiration thrombectomy, 
abciximab infusion and plain old balloon angioplasty, 
Table 1. Baseline characteristics (n = 23 patients).
Age [years] 58.5 ± 8.7
Male gender 16 (69.6%)
Diabetes 5 (21.7%)
Hypertension requiring medication 15 (65.2%)
Hyperlipidemia requiring medication 20 (87.0%)
Current smokers 14 (60.9%)
Chronic obstructive pulmonary  
disease
1 (4.3%)
Prior MI 1 (4.3%)
Prior CABG 1 (4.3%)
Peripheral vascular disease 1 (4.3%)
Kidney disease (< eGFR) 2 (8.7%)
CABG — coronary artery bypass graft; eGFR — estimated glomerular 
filtration rate; MI — myocardial infarction
Table 2. Baseline angiographic data. 
Target vessel:
LAD 4 (17.4%)
Cx 4 (17.4%)
OM 1 (4.3%)
RCA 14 (60.9%)
Lesion length [mm] 12.31 ± 4.7
Minimal luminal diameter [mm] 0.42 ± 0.66
Diameter stenosis [%] 86.88 ± 18.92
Reference vessel diameter [mm] 3.06 ± 0.65
Dmax prox [mm] 3.24 ± 0.71
Dmax dist [mm] 2.92 ± 0.68
TIMI at baseline:
0 13 (56.5%)
1 1 (4.3%)
2 7 (30.4%)
3 2 (8.7%)
MBG at baseline*:
0 1 (5.0%)
1 5 (25.0%)
2 6 (30.0%)
3 8 (40.0%)
Thrombus grade at baseline**:
0 5 (20.0%)
1 0 (0.0%)
2 1 (4.0%)
3 1 (4.0%)
4 5 (20.0%)
5 13 (52.0%)
*Analysis was performed for 20 patients with recorded angiograms 
allowing for the MBG assessment; **Analysis was performed for 
25 lesions; LAD — left anterior descending; Cx — left circumflex; 
OM — obtuse marginal branch; RCA — right coronary artery;  
Dmax prox — maximal proximal diameter; Dmax dist — maximal distal  
diameter; TIMI — Thrombolysis In Myocardial Infarction; MBG — 
myocardial blush grade
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Table 3. Procedural data. 
TIMI at final:
   3
   2
22 (95.7%)
1 (4.3%)
TFC at final [Frames] 22 ± 7.62
cTFC at final [Frames] 20.08 ± 6.31
MBG at final:
   0
   1
   2
   3 
1 (4.3%)
1 (4.3%)
3 (13.1%)
18 (78.3%)
Thrombus grade at final*:
   0
   1
   2–5
24 (96.0%)
1 (4.0%)
0 (0.0%)
Side branch closure 1 (4.3%)
Distal embolization 1 (4.3%)
Total number of scaffolds 28
Number of scaffolds per lesion:
   1
   2
22 (88.0%)
3 (12.0%)
Scaffold length [mm] 21.12 ± 8.4
Minimal luminal diameter  
in scaffold [mm]
2.55 ± 0.4
Acute gain [mm] 2.13 ± 0.75
Residual diameter stenosis [%] 11.44 ± 9.04
Reference vessel diameter [mm] 2.91 ± 0.53
Direct stenting 5 (21.7%)
Predilatation 20 (87.0%)
Manual aspiration thrombectomy 13 (56.5%)
Maximum dilating pressure [atm] 17.4 ± 3.0
Postdilatation 15 (65.2%)
Mean door­to­balloon time [min] 31.1 ± 19.3
Transradial procedure 21 (91.3%)
Medication:
Aspirin 23 (100.0%)
Clopidogrel 22 (95.7%)
Prasugrel 1 (4.3%)
Unfractionated heparin 23 (100.0%)
Use of GP IIb/IIIa inhibitors 20 (87.0%)
Peak CK­MB [ng/mL] 148.7 ± 184.7
Peak troponin I [ng/mL] 49.0 ± 57.2
*Analysis was performed for 25 lesions; CK­MB — creatinine kinase 
muscle­brain fraction; GP — glycoprotein; MBG — myocardial 
blush grade; TIMI — Thrombolysis In Myocardial Infarction;  
TFC — TIMI frame count; cTFC — corrected TIMI frame count
Table 4. Optical coherence tomography data.
Total number of analyzed struts 4019
Mean discernible struts per BVS 182.68 ± 90.45
Strut/vessel wall interaction:
Complete strut apposition [%] 95.36 ± 7.96
Malapposed strut [%] 4.64 ± 5.71
Quantitative assessment of a scaffold:
Scaffold length [mm] 23.39 ± 8.42
Minimum lumen diameter [mm] 2.56 ± 0.35
Minimum LA [mm2] 6.52 ± 1.46
Mean LA [mm2] 7.96 ± 1.63
Minimum scaffold area [mm2] 6.90 ± 1.54
Mean scaffold area [mm2] 8.17 ± 1.63
Mean ISA area [mm2] 0.38 ± 0.64
Residual area stenosis [%] 8.80 ± 24.37
Edge dissection 3 (12.0%)
Quantitative assessment  
of a reference sites:
Maximum LA in distal [mm2] 8.06 ± 3.30
Mean LA in distal [mm2] 6.71 ± 3.20
Maximum LA in proximal [ mm2] 9.94 ± 2.98
Mean LA in proximal [mm2] 8.66 ± 3.00
Scaffolds with at least  
1 malapposed strut
16 (64.0%)
Scaffolds with > 5%  
malapposed struts
2 (8.0%)
BVS — biodegradable vascular scaffold; ISA — incomplete scaffold 
area; LA — lumen area
Table 5. Clinical outcomes (n = 23 patients).
Median follow­up time [days] (IQR) 229 (199–248)
Death 0 (0.0%)
Any MI: 1 (4.3%)
Target­vessel MI: 1 (4.3%)
Q­wave MI 1 (4.4%)
Non Q­wave MI 0 (0.0%)
Non target­vessel MI: 0 (0.0%)
Q­wave MI 0 (0.0%)
Non Q­wave MI 0 (0.0%)
Target lesion revascularization 1 (4.3%)
Target vessel revascularization 1 (4.3%)
Non­target vessel revascularization 3 (13.0%)
Definite or probable scaffold  
thrombosis
1 (4.3%)
LVEF at discharge [%] 47.5 ± 8.1
IQR — interquartile range; MI — myocardial infarction; LVEF — left 
ventricular ejection fraction
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with good final angiographic result (TIMI 3). His 
LVEF dropped from 50%, directly after the primary 
index procedure to 38%. Two patients had non-TVR 
angioplasty with DES implantation. There were no 
other MACE observed in this study.
Discussion
The principal finding of this study with precise 
qualitative and quantitative protocol-based scaffold 
analysis in OCT is that BVS implantation in patients 
with STEMI is safe and effective, which was clearly 
demonstrated by excellent device, procedural and 
clinical success rates associated with over 95% 
of completely apposed scaffolds’ struts, and low 
incidence of residual stenosis and edge dissections.
Dilletti et al. [15] reported 22.6% of scaffolds 
with more than 5% of malapposed struts, which 
is regarded as significant malapposition according 
to commonly used definition in previous studies 
[27, 28]. In patients with acute coronary syn-
dromes, treated with the currently recommended 
DES implantation, the rate of malapposed stents 
reached up to 30% [28, 29]. In our study, only 
8.0% of scaffolds were found to be significantly 
malapposed. Such a low rate of malapposition may 
be partially related to the small number of study 
patients. However, the more likely explanation is 
the fact that the OCT guidance used in all patients 
influenced the operator’s performance, leading to 
additional balloon postdilatations in 21.7% of cases. 
Although the BVS implantation technique employs 
the same principles utilized in conventional metal-
lic stent angioplasty, the adequate assessment of 
optimal expansion of the device, based solely upon 
angiography, may be difficult due to radiolucent 
features of the BVS.
A relatively high thrombus burden (grade 4 or 
5 in 72%) was observed in our group before BVS 
implantation. It has been hypothesized that due to 
the higher profile of BVS, its placement in acute 
thrombotic lesions might require a more intense 
lesion preparation compared with standard metal-
lic stents, which may increase the risk of distal 
embolization, no-reflow phenomenon and reduced 
final TIMI flow [15]. Nevertheless, TIMI 3 flow and 
MBG rate were high and comparable with those 
reported in previous studies on pPCI with stents 
[30–32]. Distal embolization occurred only in 
1 (4.3%) case and no-reflow phenomenon in none. 
These findings are in line with recently published 
studies in STEMI population treated with the same 
type of BVS [15, 16].
STEMI is an independent predictor for acute 
or late stent thrombosis [33–35]. In our study, 
one sub-acute stent thrombosis was observed. 
However, due to the fact that it occurred 5 days 
after the patient had stopped (on his own) dual 
antiplatelet therapy, it seems to be a consequence 
of inappropriate platelet inhibition rather than 
a device-related event.
Sequestration of thrombus burden between 
the struts and vessel wall may lead to late scaffold 
malapposition and/or scaffold thrombosis in case 
of its resolution before the struts dissolution. As 
a consequence, the turbulent blood flow around scaf-
fold’s struts and activation of platelet aggregation on 
the surface of struts might facilitate new thrombus 
formation. However, the assessment of the risk of 
possible late acquired malapposition and scaffold 
thrombosis requires serial OCT examinations.
The results from the prospective registry and 
currently available body of evidence provide valu-
able clinical insights in favor of everolimus-eluting 
BVS implantation in STEMI population. However, 
the current body of evidence is still limited due to 
a small number of patients and does not allow to 
draw any firm conclusions regarding wider applica-
tion of BVS in pPCI in everyday clinical practice.
Limitations of the study
The main limitation of this study is the low 
number of patients, strict angiographic and clinical 
inclusion/exclusion criteria and its non-randomized 
design. The report is of preliminary character and 
further investigations with a head-to-head com-
parison of BVS with the current standard of care 
are needed to assess the role of this device in the 
treatment of patients with STEMI.
Conclusions
The presented results demonstrated that BVS 
implantation in selected STEMI patients is safe and 
feasible. The acute OCT evaluation confirmed excel-
lent performance with appropriate scaffold expansion 
and low rate of malapposition. Further randomized 
controlled trials are necessary to confirm the safety 
and efficacy of BVS in this group of patients.
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